Standout Papers

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovas... 2010 2026 2015 2020 1.1k
  1. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events (2015)
    Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine
  2. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial (2010)
    Frederick J. Raal, Raúl D. Santos et al. The Lancet
  3. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial (2014)
    Frederick J. Raal, Narimon Honarpour et al. The Lancet
  4. A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia (2014)
    Dirk Blom, Tomas Hala et al. New England Journal of Medicine
  5. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study (2012)
    Marina Cuchel, Emma A. Meagher et al. The Lancet
  6. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia (2015)
    John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal
  7. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome (2019)
    Joseph L. Witztum, Daniel Gaudet et al. New England Journal of Medicine
  8. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial (2015)
    Christopher P. Cannon, Bertrand Cariou et al. European Heart Journal
  9. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145) (2014)
    Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology

Immediate Impact

3 by Nobel laureates 16 from Science/Nature 104 standout
Sub-graph 1 of 18

Citing Papers

Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
2024 Standout
Efficacy and Safety of an Investigational Single-Course CRISPR Base-Editing Therapy Targeting PCSK9 in Nonhuman Primate and Mouse Models
2022 Standout
70 intermediate papers

Works of Dirk Blom being referenced

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels
2015
Severe hypertriglyceridaemia as a result of familial chylomicronaemia: the Cape Town experience.
2008
and 34 more

Author Peers

Author Last Decade Papers Cites
Dirk Blom 6109 2183 1861 1936 157 7.9k
Fernando Civeira 4787 2340 1011 1832 282 7.8k
G. Kees Hovingh 7161 3865 1438 2559 203 11.2k
Sergio Fazio 4418 2197 796 1845 141 7.7k
Leiv Ose 3537 1501 604 897 160 5.7k
Marcello Arca 2860 2032 343 2012 216 6.2k
Frederick J. Raal 10561 3499 3340 3021 323 13.7k
A. David Marais 3386 1493 463 1158 129 4.9k
Jan Albert Kuivenhoven 5854 4324 329 2756 155 10.3k
David Kallend 5136 2483 1103 1737 98 7.4k
Jean Bergeron 3178 1783 1039 1115 80 5.9k

All Works

Loading papers...

Rankless by CCL
2026